Primary Aldosteronism and Drug Resistant Hypertension: A "Chicken-Egg" Story

被引:4
作者
Lenzini, L. [1 ,2 ]
Pintus, G. [1 ]
Rossitto, G. [1 ]
Seccia, T. M. [1 ]
Rossi, G. P. [1 ]
机构
[1] Univ Padua, Dept Med, Internal & Emergency Med Unit, DIMED, Padua, Italy
[2] Univ Hosp, Via Giustiniani 2, Padua 35128, Italy
关键词
primary aldosteronism; drug resistant hypertension; mineralocorticoid receptor antagonists; POSITRON-EMISSION-TOMOGRAPHY; CHRONIC KIDNEY-DISEASE; PLASMA-RENIN ACTIVITY; K+ CHANNEL MUTATIONS; SOMATIC MUTATIONS; ADENOMAS; ADRENALECTOMY; OUTCOMES; CT; HYPERALDOSTERONISM;
D O I
10.1055/a-2073-3202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-resistant arterial hypertension ( RH) is a major risk factor for cardiovascular disease, often due to overlooked underlying causes. Identification of such causes poses significant clinical challenges. In this setting, primary aldosteronism (PA) is a frequent cause of RH and its prevalence in RH patients is likely higher than 20 %. The pathophysiological link between PA and the development and maintenance of RH involves target organ damage and the cellular and extracellular effects of aldosterone excess that promote pro-inflammatory and pro-fibrotic changes in the kidney and vasculature. The feasibility of adrenal vein sampling in PA patients with RH, and the clinical benefit achieved by adrenalectomy, further emphasize the need to implement systematic screening for this common form of secondary hypertension in the management of a high-risk population as RH patients. We herein review the current knowledge of the factors that contribute to the RH phenotype with a focus on PA and discuss the issues regarding the screening for PA in this setting and the therapeutic approaches (surgical and medical) aimed at resolving RH caused by PA.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 96 条
  • [1] Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    Agarwal, Rajiv
    Filippatos, Gerasimos
    Pitt, Bertram
    Anker, Stefan D.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Gebel, Martin
    Ruilope, Luis M.
    Bakris, George L.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (06) : 474 - +
  • [2] Are Women More at Risk of False-Positive Primary Aldosteronism Screening and Unnecessary Suppression Testing than Men?
    Ahmed, Ashraf H.
    Gordon, Richard D.
    Taylor, Paul J.
    Ward, Gregory
    Pimenta, Eduardo
    Stowasser, Michael
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (02) : E340 - E346
  • [3] Aryal S R., 2021, J AM HEART ASSOC, P10
  • [4] Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
    Azizan, Elena A. B.
    Poulsen, Hanne
    Tuluc, Petronel
    Zhou, Junhua
    Clausen, Michael V.
    Lieb, Andreas
    Maniero, Carmela
    Garg, Sumedha
    Bochukova, Elena G.
    Zhao, Wanfeng
    Shaikh, Lalarukh Haris
    Brighton, Cheryl A.
    Teo, Ada E. D.
    Davenport, Anthony P.
    Dekkers, Tanja
    Tops, Bas
    Kuesters, Benno
    Ceral, Jiri
    Yeo, Giles S. H.
    Neogi, Sudeshna Guha
    McFarlane, Ian
    Rosenfeld, Nitzan
    Marass, Francesco
    Hadfield, James
    Margas, Wojciech
    Chaggar, Kanchan
    Solar, Miroslav
    Deinum, Jaap
    Dolphin, Annette C.
    Farooqi, I. Sadaf
    Striessnig, Joerg
    Nissen, Poul
    Brown, Morris J.
    [J]. NATURE GENETICS, 2013, 45 (09) : 1055 - +
  • [5] Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
    Azizi, Michel
    Sapoval, Marc
    Gosse, Philippe
    Monge, Matthieu
    Bobrie, Guillaume
    Delsart, Pascal
    Midulla, Marco
    Mounier-Vehier, Claire
    Courand, Pierre-Yves
    Lantelme, Pierre
    Denolle, Thierry
    Dourmap-Collas, Caroline
    Trillaud, Herve
    Pereira, Helena
    Plouin, Pierre-Francois
    Chatellier, Gilles
    [J]. LANCET, 2015, 385 (9981) : 1957 - 1965
  • [6] Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
    Bakris, George L.
    Agarwal, Rajiv
    Anker, Stefan D.
    Pitt, Bertram
    Ruilope, Luis M.
    Rossing, Peter
    Kolkhof, Peter
    Nowack, Christina
    Schloemer, Patrick
    Joseph, Amer
    Filippatos, Gerasimos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2219 - 2229
  • [7] Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension
    Beeftink, Martine M. A.
    van der Sande, Nicolette G. C.
    Bots, Michiel L.
    Doevendans, Pieter A.
    Blankestijn, Peter J.
    Visseren, Frank L. J.
    Voskuil, Michiel
    Spiering, Wilko
    [J]. HYPERTENSION, 2017, 69 (05) : 927 - 932
  • [8] Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension
    Beuschlein, Felix
    Boulkroun, Sheerazed
    Osswald, Andrea
    Wieland, Thomas
    Nielsen, Hang N.
    Lichtenauer, Urs D.
    Penton, David
    Schack, Vivien R.
    Amar, Laurence
    Fischer, Evelyn
    Walther, Anett
    Tauber, Philipp
    Schwarzmayr, Thomas
    Diener, Susanne
    Graf, Elisabeth
    Allolio, Bruno
    Samson-Couterie, Benoit
    Benecke, Arndt
    Quinkler, Marcus
    Fallo, Francesco
    Plouin, Pierre-Francois
    Mantero, Franco
    Meitinger, Thomas
    Mulatero, Paolo
    Jeunemaitre, Xavier
    Warth, Richard
    Vilsen, Bente
    Zennaro, Maria-Christina
    Strom, Tim M.
    Reincke, Martin
    [J]. NATURE GENETICS, 2013, 45 (04) : 440 - 444
  • [9] Bioletto F., 2022, INT J MOL SCI, P23
  • [10] Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
    Blasi, ER
    Rocha, R
    Rudolph, AE
    Blomme, EAG
    Polly, ML
    McMahon, EG
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (05) : 1791 - 1800